Canalevia®-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA
SAN FRANCISCO, CA / ACCESSWIRE / June 21, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, announced today that the company is exhibiting at the American College of Veterinary Internal Medicine (ACVIM) Forum, which takes place June 23 – 25, 2022 in Austin, TX, as part of ongoing commercial launch activities for Canalevia-CA1 (crofelemer delayed-release tablets). Canalevia-CA1, the company’s FDA conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea (CID) in dogs, is now available from multiple leading veterinary distributors in the US
Jaguar Animal Health is sponsoring the two below events at the ACVIM Forum:
Jaguar Animal Health is showcasing Canalevia-CA1 at exhibit booth number 521 at the ACVIM Forum. Additional information about this event can be found on the conference website by clicking here.
About Chemotherapy-Induced Diarrhea (CID) in Dogs
Due to the increasing number of chemotherapeutic agents being adopted by veterinarians and veterinary oncologists, chemotherapy is almost becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment,1 and managing side effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the US veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients’ chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID.
Crofelemer is a novel, oral plant-based medicine extracted and purified from the red bark sap, also referred to as “dragon’s blood,” of the medicinal Croton lechleri tree in the Amazon Rainforest. Jaguar Health’s wholly owned subsidiary, Napo Pharmaceuticals, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities. Additionally, crofelemer is the active ingredient in an antidiarrheal that is approved by the FDA under botanical guidance and indicated for the symptomatic relief of noninfectious diarrhea in adult human patients with HIV/AIDS on antiretroviral therapy.
Canalevia-CA1 (crofelemer delayed-release tablets) is the first and only prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is an oral formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Canalevia-CA1 is conditionally approved by the FDA under application number 141-552. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for a full approval. Jaguar has received Minor Use in a Major Species (MUMS) designation from the FDA for Canalevia-CA1 to treat CID in dogs. FDA has established a “small number” threshold for minor use in each of the seven major species covered by the MUMS act. The small number threshold is currently 70,000 for dogs, representing the largest number of dogs that can be affected by a disease or condition over the course of a year and still have the use qualify as a minor use.
Important Safety Information About Canalevia-CA1
For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.
Warning: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling.Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
About Jaguar Health, Jaguar Animal Health, Napo Pharmaceuticals, & Napo Therapeutics
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Jaguar Animal Health is a tradename of Jaguar Health. Jaguar Health’s wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human pharmaceuticals from plants harvested responsibly from rainforest areas. Our crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics SpA (f/k/a Napo EU SpA), an Italian corporation established by Jaguar Health in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe.
For more information about Jaguar Health, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com.
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that it will exhibit at the 2022 ACVIM Forum. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend, ” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Some of the factors that could affect our actual results are included in the periodic reports on Form 10-K and Form 10-Q that we file with the Securities and Exchange Commission. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
1 Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomized controlled study. J Small Animal Practice. 2014;55:391-398
Jaguar Health, Inc.
SOURCE: Jaguar Health, Inc.
View source version on accesswire.com: